Opioid Indication Change Could Draw Legal Challenge From Physicians Group Seeking More Restrictions
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA tells sponsors to revise the indication for the ER/LA analgesics to highlight appropriate patient selection rather than severity of pain and orders post-marketing studies to identify a dose and duration-of-treatment associated with higher rates of abuse, misuse, addiction, overdose and death.